Clinical trials: Movement Abnormalities
Parkinson's Disease
Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
To evaluate the effects of Memantine on non-motor symptoms in patients with Parkinson's disease. Parkinson's disease (PD) affects about one million people in the United States.
- Trial name
- NCT00646204
- Testing
- Memantine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Baylor College of Medicine
Parkinson Disease
Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease
The objectives of this trial conducted in early Parkinson's disease (PD) patients are: To assess if patients with early Parkinson's disease (PD) can be successfully switched (overnight switching) from Pramipexole (PPX) Immediate…
- Trial name
- NCT00558025
- Testing
- Pramipexole Extended Release, Pramipexole Immediate Release
- Where
- 36 sites in France, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Boehringer Ingelheim
Progressive Supranuclear Palsy
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists.
- Trial name
- NCT00382824
- Testing
- Coenzyme Q10
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Lahey Clinic
Parkinson's Disease
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.
- Trial name
- NCT02337725
- Testing
- TVP-1012
- Where
- 55 sites in Japan
- Volunteers
- 244 people
- Sponsor
- Takeda
Parkinson's Disease
The Effect of Donepezil on Gait and Balance in Parkinson's Disease
This study involves Parkinson's disease (PD). Symptoms include slow movement, tremor, and muscle rigidity. Current medications for the treatment of PD do not improve gait and balance difficulties in individuals with PD.
- Trial name
- NCT01521117
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Oregon Health and Science University
Parkinson Disease, Idiopathic Parkinson Disease
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
The primary purpose of this extension study is to assess the long-term safety and tolerability of preladenant in participants from parent studies NCT01155466 [P04938] and NCT01227265 [P07037] with moderate to severe Parkinson's…
- Trial name
- NCT01215227
- Testing
- Preladenant, Rasagiline
- Volunteers
- 839 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Parkinson's Disease
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment…
- Trial name
- NCT00660673
- Testing
- Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 262 people
- Sponsor
- AbbVie
Parkinson's Disease
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
The purpose of this study is to evaluate the long-term safety of TVP-1012 (1 mg/day) in Japanese participants with early Parkinson's disease.
- Trial name
- NCT02337751
- Testing
- TVP-1012 1mg
- Where
- 56 sites in Japan
- Volunteers
- 198 people
- Sponsor
- Takeda
Parkinson Disease
Nilotinib in Parkinson's Disease
This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.
- Trial name
- NILO-PD (NCT03205488)
- Testing
- Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
- Where
- 24 sites in United States
- Volunteers
- 76 people
- Sponsor
- Northwestern University
Parkinson Disease
Amped-PD: Amplifying Physical Activity Through Music in Parkinson Disease
Regular, habitual exercise is a critical component of the long-term management of Parkinson disease (PD). However, PD-specific motor (e.g. slow and diminished movements, variable step timing) and non-motor (e.g.
- Trial name
- Amped-PD (NCT05421624)
- Testing
- Digital music therapeutic, Active-Control
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Boston University Charles River Campus
Parkinson's Disease
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
This study will evaluate an oral fixed-dose, once daily product that combines pramipexole and rasagiline for the treatment of early Parkinson's disease.
- Trial name
- NCT01968460
- Testing
- P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
- Where
- 29 sites in United States, Israel
- Volunteers
- 149 people
- Sponsor
- Pharma Two B Ltd.
Parkinson Disease
Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a…
- Trial name
- NCT03368170
- Testing
- Mesdopetam (IRL790)
- Where
- 20 sites in Sweden, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Integrative Research Laboratories AB
Huntington Disease, Chorea
Citalopram to Enhance Cognition in HD
This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1.
- Conditions
- Huntington Disease, Chorea, Executive Dysfunction
- Trial name
- CIT-HD (NCT00271596)
- Testing
- 20mg daily citalopram
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Parkinson's Disease, Essential Tremor
RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)
The purpose of this study is to assess the recharge feature of the Activa RC System in patients who are receiving Deep Brain Stimulation (DBS) for Parkinson's Disease (PD), Essential Tremor (ET), or dystonia.
- Conditions
- Parkinson's Disease, Essential Tremor, Dystonia
- Trial name
- RECHARGE (NCT00998660)
- Testing
- Activa RC
- Where
- 11 sites in United States, Austria and 4 more
- Volunteers
- 100 people
- Sponsor
- MedtronicNeuro
Angelman Syndrome
Minocycline in the Treatment of Angelman Syndrome
There is mounting evidence to suggest that a treatment for Angelman syndrome is not just possible, but probable. The lack of known molecular targets associated with AS has hampered the development of specific therapeutics.
- Trial name
- NCT01531582
- Testing
- minocycline
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of South Florida
Gait Disorders, Neurologic, Parkinson Disease
Bracing for Walking in Parkinson's Disease
Parkinson disease (PD) is a progressive neurological disease that results in characteristic gait dysfunction. Gait problems include decreased velocity, decreased stride length, difficulty with initiation of gait, postural…
- Trial name
- NCT03192046
- Testing
- Carbon Fiber Ankle Foot Orthosis (AFO), Standardized walking/exercise program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Texas Southwestern Medical Center
Parkinson's Disease
Aerobic Exercise in Parkinson's Disease
Parkinson's disease (PD) is an incurable brain illness that afflicts more than one million Americans, including many aging Veterans.
- Trial name
- LTAE-PD (NCT03808675)
- Testing
- Aerobic walking, Usual care with PD specific health education
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- VA Office of Research and Development
Parkinson's Disease
Validation of Dyskinesia Rating Scales
This study will evaluate the responsiveness of a variety of available dyskinesia rating scales to treatment with amantadine or placebo in Parkinson's disease patients with dyskinesia.
- Trial name
- NCT01071395
- Testing
- Amantadine
- Where
- 8 sites in United States, Austria and 2 more
- Volunteers
- 68 people
- Sponsor
- Rush University Medical Center
Huntington Disease, Irritability
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
The purpose of this study is to assess efficacy and safety of dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) in patients with irritability due to Huntington's disease.
- Trial name
- NCT03854019
- Testing
- Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Parkinson Disease, Parkinson's Disease and Parkinsonism
STEM-PD Open Label Extension (OLE)
This study seeks to establish the safety and efficacy of extended twice daily time-varying caloric vestibular stimulation treatments for treating symptoms associated with Parkinson's disease.
- Trial name
- NCT04799418
- Testing
- Open Label Extension Study
- Where
- 15 sites in United States
- Volunteers
- 148 people
- Sponsor
- Scion NeuroStim